SAM S. MILLER, M.D.; GLEN W. SIZEMORE, M.D.; SHELDON G. SHEPS, M.D., F.A.C.P.; GERTRUDE M. TYCE, Ph.D.
Serum calcium, serum immunoreactive parathyroid hormone (PTH), and plasma immunoreactive calcitonin were measured in 12 patients with catecholamine-secreting tumors. Only two patients had high serum calcium and immunoreactive PTH concentrations (one also had high basal immunoreactive calcitonin); in both, the hypercalcemia persisted after removal of their pheochromocytomas but was corrected by removal of hyperplastic parathyroid glands and medullary thyroid carcinomas. Of the 10 patients with normal serum calcium and immunoreactive PTH concentrations, 2 had high immunoreactive calcitonin concentrations and medullary thyroid carcinomas alone were found. Our results suggest that  hypercalcemia occurs infrequently in patients with pheochromocytoma,  chronic circulating catecholamine excess does not cause increased immunoreactive PTH or immunoreactive calcitonin secretion in patients with pheochromocytoma, and  the parathyroid disease in patients with pheochromocytoma is a genetically determined component of multiple endocrine neoplasia.
MILLER SS, SIZEMORE GW, SHEPS SG, TYCE GM. Parathyroid Function in Patients with Pheochromocytoma. Ann Intern Med. ;82:372–375. doi: 10.7326/0003-4819-82-3-372
Download citation file:
Published: Ann Intern Med. 1975;82(3):372-375.
Adrenal Disorders, Endocrine and Metabolism, Endocrine Cancer, Hematology/Oncology, Parathyroid Disorders.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use